S-1
Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and HospitalPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
109 Active assets in the Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hycamtin AbbVie | Phase 4 | BB |
Irinotecan Sichuan University | Phase 4 | BB |
Carboplatin University of Maryland, Baltimore | Phase 4 | BB |
ETOPOSIDE Sichuan University | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Same molecule, other indications
S-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →